Bio News
Danish drugmaker Novo Nordisk said it plans to launch at least five blockbuster drugs by 2030 and generate more than $23 billion in annual revenue by 2035 from its current pipeline.
At a capital markets day event in London, Novo Nordisk unveiled a strategy to regain investor confidence after losing its lead in the obesity treatment market to rival Eli Lilly.
Novo Nordisk has lost more than two-thirds of its market capitalization over the past two years or so, and its shares fell an additional 8% in morning trading despite the announcement.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
